Readthrough of Premature Termination Codons in the Adenomatous Polyposis Coli Gene Restores Its Biological Activity in Human Cancer Cells by Floquet, Célia et al.
Readthrough of Premature Termination Codons in the
Adenomatous Polyposis Coli Gene Restores Its Biological
Activity in Human Cancer Cells
Ce ´lia Floquet
1,2, Jean-Pierre Rousset
1,2, Laure Bidou
1,3*
1Institut de Ge ´ne ´tique et Microbiologie, CNRS, UMR 8621, Orsay, France, 2Universite ´ Paris-Sud, Orsay, France, 3Universite ´ Pierre et Marie Curie, Paris, France
Abstract
The APC tumor suppressor gene is frequently mutated in human colorectal cancer, with nonsense mutations accounting for
30% of all mutations in this gene. Reintroduction of the WT APC gene into cancer cells generally reduces tumorigenicity or
induces apoptosis. In this study, we explored the possibility of using drugs to induce premature termination codon (PTC)
readthrough (aminoglycosides, negamycin), as a means of reactivating endogenous APC. By quantifying the readthrough of
11 nonsense mutations in APC, we were able to identify those giving the highest levels of readthrough after treatment. For
these mutations, we demonstrated that aminoglycoside or negamycin treatment led to a recovery of the biological activity
of APC in cancer cell lines, and showed that the level of APC activity was proportional to the level of induced readthrough.
These findings show that treatment with readthrough inducers should be considered as a potential strategy for treating
cancers caused by nonsense mutations APC gene. They also provide a rational basis for identifying mutations responsive to
readthrough inducers.
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Introduction
The APC (adenomatous polyposis coli) tumor suppressor gene
encodes a 311 kDa multidomain protein with binding sites for
numerous partners, including microtubules, axin and beta-catenin
[1]. This protein functions as a negative regulator of the Wnt
pathway which is implicated in the transactivation of target genes
such as the oncogene c-myc and the cyclin D1 gene [2]. The APC
gene is mutated in 80% of colon cancers and mutations occur
early in the development of most polyploid colorectal cancers. It
has been shown that reintroduction of the wild-type APC gene
into cancer cells generally reduces tumorigenicity or induces
apoptosis [3,4]. Overall, 30% of all mutations in this gene are
nonsense mutations [5].
In the last few years, certain antibiotics have been shown to
interfere with the mammalian ribosome, inducing the readthrough
of premature stop codons (PTCs). Aminoglycosides are the
antibiotics most frequently studied in this respect, and multiple
studies have suggested that these drugs could be used in innovative
strategies for the treatment of genetic diseases caused by nonsense
mutations (for review [6,7,8]). The dipeptide antibiotic negamycin
is not structurally related to aminoglycosides [9] and has been
found to be more effective than gentamicin for promoting the
readthrough of some nonsense mutation [10]. This drug may thus
constitute an attractive alternative treatment for patients carrying
a nonsense mutation.
In a recent study, we demonstrated that even a modest
aminoglycoside-induced readthrough level (6%) triggered apoptosis
of cancer cells harboring a nonsense-mutated p53 gene [11]. These
results provided the proof-of-concept that readthrough inducers can
be used in the treatment of cancers linked to the presence of a
nonsense mutationin a tumor suppressor gene. In the present study,
we investigate the possibility of extending this approach to cancer
linked to a nonsense mutation in APC gene. Recently, Zilberberg et
al showed that readthrough inducers improved clinical symptoms of
tumorigenesis in a mouse model carrying a nonsense mutation in
the APC gene. However, the link between the lower level of tumor
development and PTC readthrough was not established [12]. It is
becoming increasingly evident that only a subset of nonsense
mutations would benefit from gentamicin treatment, depending on
their nucleotide context [13,14,15,16].
We evaluated readthrough efficiency for 11 nonsense mutations
involved in colorectal cancer, with a view to identifying the
nonsense mutations in the APC gene the most responsive to
readthrough-inducing treatments. For the mutations with the
highest readthrough levels, including an endogenous mutation,
antibiotic treatment resulted in recovery of the biological activity
of APC.
Results and Discussion
Identification of APC nonsense mutations responsive to
aminoglycoside treatment
We studied 11 nonsense mutations found in 23% of cancer cells
carrying a nonsense mutation in the APC gene (T. Soussi, personal
communication). Readthrough efficiency has been shown to
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24125depend on the nature of the sequences surrounding the stop codon
[13,17,18,19]. Thus, for each mutation, we inserted a region
encompassing the surrounding context (27 nucleotides) into the
dual reporter vector pAC99 (Table 1). Readthrough was
quantified in NIH3T3 cells transiently transfected with the dual
reporter vector, in the presence or absence of gentamicin
(Figure 1). Readthrough rates ranged from 0.01% (Q1131X) to
0.2% (L360X) for basal readthrough, and from 0.09% (APC
Q789X) to 1.6% (L360X) in the presence of 800 mg/ml
gentamicin. Similar variations in basal readthrough levels and
responsiveness to aminoglycosides have been reported in several
previous studies [13,18]. We also tested another antibiotic,
amikacin, which gave readthrough levels similar to or lower than
those obtained with gentamicin (data not shown). This result is
consistent with a previous study from Howard et al who have
compared readthrough activity of several aminoglycosides [20].
We assessed whether readthrough levels were similar in cells of
colon origin, by also evaluating the readthrough directed by each
nonsense mutation in the cancer colorectal DLD-1 cell line. The
results obtained were similar to those for NIH3T3 cells (data not
shown).
For further characterization, we focused on the L360X and
R1114X nonsense mutations, which displayed the highest levels of
readthrough in the presence of the aminoglycoside gentamicin
(1.6% and 0.7%, respectively). For the two selected nonsense
mutations, we quantified the readthrough levels obtained in the
presence of various concentrations of G418 (geneticin), because
this antibiotic is the most potent readthrough inducer of the
aminoglycosides [11,21,22]. Both nonsense mutations displayed a
dose-dependent response to G418, resulting in readthrough levels
greater than those observed for gentamicin, reaching 2.3% for
L360X and 1.8% for R1114X (Figure 2 A and 2B respectively).
The readthrough levels obtained in the presence of the dipeptide
negamycin were lower than (L360X) or similar (R1114X) to those
obtained with gentamicin (Figure 2 A and 2B respectively).
Readthrough level depends on the nature of the stop codon and
the surrounding nucleotide context, but the rules governing
readthrough level are complex and remain to be determined for
mammalian cells. The presence of a C residue immediately after
the stop codon (+4) is correlated with a high level of readthrough,
although this does not seem to be the sole determinant of
readthrough level. Several studies have also demonstrated that
only a few nonsense mutations give ‘‘significant’’ readthrough in
the presence of gentamicin. In this study, only two of the eleven
nonsense mutations tested, L360X and R1114X, displayed
gentamicin-induced readthrough levels greater than 0.5%, but
only L360X had a C residue in the +4 position. The R1114X
mutation would therefore have been discarded if this had been the
only criterion used to identify mutations responding well to
readthrough inducers. Our approach thus provides a rational
strategy for identifying patients likely to benefit from treatment
with readthrough inducers.
Recovery of APC biological activity from the APC L360X
cDNA after aminoglycoside treatment
We then investigated whether aminoglycoside treatment
induced detectable levels of biological activity for an APC
protein produced from a cDNA bearing the L360X mutation.
Active APC mediates the sequestration of beta-catenin in the
cytoplasm, thus preventing the interaction of this molecule with
the transactivation factor TCF required for the expression of
target genes. APC protein activity was evaluated by determin-
ing the ability of this protein to bind beta-catenin, using a
reporter construct containing TCF/beta-catenin binding sites
inserted upstream from the luciferase firefly gene (pTopGlow)
[23]. In this reporter system, the interaction between active
APC and beta-catenin results in the inhibition of firefly
luciferase expression.
DLD-1 cells devoid of functional APC protein (APC del 1 bp
1406) were transfected with the pCMV expression vector
containing either WT or L360X mutant APC cDNA, together
with pTopGlow (Figure 2C). Transfection with the WT APC
vector resulted in levels of firefly expression one tenth those
obtained after transfection with an empty vector. Without
treatment, L360X displayed residual levels of activity, probably
due to the incomplete loss-of-function of this allele, as residual
Table 1. APC nonsense mutations.
WT Codon Mutation * Sequence 59. .39
1 Mutation Frequency
{
CGA R213X GAT ATG GAA AAA TGA GCA CAG CGA 2.6%
TTA L360X CTC ATC CAG CTT TGA CAT GGC AAT {
CAG Q789X CAT CGT AGT AAG TAG AGA CAC AAG 0.1%
TCA S811X GAT GAT AAT AGG TGA GAC AAT TTT 0.3%
GAG E853X GAT AGA AGT TTG TAG AGA GAA CGC 0.3%
CGA R1114X TCA GAA ACA AAT TGA GTG GGT TCT 2.6%
CAA Q1131X CAG TCT TTG TGT TAA GAA GAT GAC 0.1%
GAA E1309X GCA GAA ATA AAA TAA AAG ATT GGA 1.8%
CAG Q1367X AAA AGT GGT GCT TAG ACA CCC AAA 1.8%
CAA Q1429X GAT AGC CCT GGA TAA ACC ATG CCA 0.9%
CGA R1450X GCT CAA ACC AAG TGA GAA GTA CCT 12.5%
All mutations studied23.2%
*Mutations are named by the position and the nature of the wild-type amino acid in APC protein sequence.
1These nonsense mutation sequences were inserted into the dual reporter vector in order to determine readthrough level.
{Frequencies were given relative to total nonsense mutations listed for APC gene.
{This nonsense mutation was reported in [33].
doi:10.1371/journal.pone.0024125.t001
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positions [23]. The highest dose of G418 decreased luciferase
activity by a factor of 2.5, demonstrating the production of a
functional APC protein on aminoglycoside treatment. G418
repressed luciferase activity in a dose-dependent manner correlat-
ed with the readthrough levels measured in DLD-1 cells
(Figure 2A). Treatment with the aminoglycosides gentamicin or
amikacin, or with negamycin also triggered the repression of
luciferase activity, indicating the synthesis of an active APC
protein (Figure 2C). For each treatment, protein activity was
correlated with the level of readthrough level measured in the dual
reporter system (Figure 2A and 2C). We used Spearman’s
nonparametric correlation test (two-tailed) to assess the signifi-
cance of this correlation. We found that there was a strong, highly
significant correlation (rs =20.95, p,0.0001) between read-
through level and the decrease in luciferase activity. Thus, both
aminoglycoside and the dipeptide negamycin can induce APC
biological activity from a mutant cDNA, and the level of activity is
proportional to readthrough level. As a control, we used the
pFopGlow vector containing mutated TCF/beta-catenin binding
sites. With this vector, no significant change was observed after
aminoglycoside or negamycin treatment (data not shown).
Recovery of APC biological activity from the endogenous
R1114X APC gene after aminoglycoside treatment
We then investigated whether the aminoglycoside treatment
of endogenous nonsense mutations would give similar results.
LoVo cells (APC R1114X) were transfected with the reporter
plasmid pTopGlow and left untreated or treated with G418 or
negamycin. The activity of the luciferase firefly reporter gene
was maximal in the absence of treatment and was set at 100%,
reflecting the lack of activity of the APC protein. Treatment
with negamycin and G418 decreased pTopGlow firefly
luciferase activity to 50% and 18% the reference value,
respectively (Figure 2D). Activity level was correlated with
readthrough efficiency (Figure 2B). Surprisingly, gentamicin
treatment, despite promoting levels of readthrough similar to
those obtained with negamycin,d i dn o td e c r e a s ep T o p G l o w
firefly luciferase activity (data not shown). Thus, readthrough
efficiency is not the only determinant for the recovery of full-
length protein activity. Indeed, PTC readthrough corresponds
to the incorporation of a near-cognate aminoacyl tRNA
[24,25,26,27] (complementary to two of the three nucleotides
of a stop codon), potentially resulting in the replacement of the
normal residue by an amino acid incompatible with the stability
or activity of the full-length protein [10]. It is possible that
different amino acids are incorporated in place of the stop
codon in the presence of these two drugs, with only negamycin
treatment leading to the incorporation of (an) amino acid(s)
compatible with the biological activity of the protein. This
situation might arise due to the different modes of activity of
these drugs: aminoglycosides seem to bind exclusively to the
decoding center [28], whereas negamycin has been shown to
bind not only to the A site of the small ribosomal subunit [9],
but also to the wall of the nascent chain exit tunnel of the large
ribosomal subunit [29]. We might therefore expect the subset of
natural suppressor tRNAs selected to be different after
aminoglycoside and negamycin treatments.
As for the other mutation tested, luciferase expression from
pFopGlow harboring mutated TCF/beta-catenin binding sites was
not significantly affected by antibiotic treatment (data not shown).
We checked that active APC protein was actually responsible for
the observed decrease in firefly luciferase expression, using a
siRNA specifically targeting the APC mRNA. We first used RT-
PCR to check that the siRNA effectively decreased APC mRNA
levels (figure 2E). LoVo cells were cotransfected with the
pTOPGlow reporter plasmid and siRNA targeting or not targeting
APC.
After G418 treatment (200 mg/ml), the APC-targeting siRNA
gave a decrease in luciferase activity two times lower than that
observed in absence of siRNA, whereas the non specific siRNA
had no effect on luciferase inhibition (Figure 2D). Thus, the effect
on the reporter system was detected specifically in the presence of
APC mRNA indicating that it is mediated by an active APC
protein.
For these two mutants, we investigated the ability of
aminoglycoside treatment to restore the production of full-length
APC protein. We were able to detect the full-length APC protein
in HeLa cells (APC WT), but this protein was not detectable after
drug treatment in either LoVo cells (R1114X) or DLD-1 cells
Figure 1. Identification of APC nonsense mutations responsive to aminoglycoside treatment. Readthrough efficiencies for 11 nonsense
mutations in the APC gene were assessed in NIH3T3 cells with and without gentamicin (800 mg/ml) treatment for 24 h. Two nonsense mutations
(L360X and R1114X) displayed levels of gentamicin-induced readthrough of more than 0.5%. Means values are presented, together with the standard
error of the mean (SEM) (n=5).
doi:10.1371/journal.pone.0024125.g001
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detection was probably due to the limitations of the technique for
detecting small amounts of a large (311 kDa) protein. These
findings suggest that low levels of APC protein may be sufficient to
regulate the activity of the TCF/beta-catenin transcriptional
complex.
Figure 2. APC biological activity is correlated with antibiotic-induced readthrough level in human colorectal cancer cells.
(A) Readthrough efficiencies for APC L360X nonsense mutations were determined in DLD-1 cells in the presence of G418 (10, 25, 50, 100 and
200 mg/ml), negamycin (1 mg/ml), amikacin (2 mg/ml) or gentamicin (800 mg/ml). (B) Readthrough efficiencies for APC R1114X nonsense
mutations were determined in NIH3T3 cells in the presence of G418 (50, 100 and 200 mg/ml) or negamycin (1 mg/ml). The readthrough
efficiencies in DLD-1 cells were consistent with those in NIH3T3 cells (data not shown). (C) Aminoglycoside treatment restored APC activity.
APC binding to beta-catenin (reppression of the pTOPGlow reporter) is restored by the treatment of DLD-1 cells transiently transfected with
cDNA APC L360X with G418 (10, 25, 50, 100 and 200 mg/ml), negamycin (1 mg/ml), amikacin (2 mg/ml) or gentamicin (800 mg/ml). (D) APC
binding to beta-catenin (repression of pTOPGlow reporter) is restored by the treatment of LoVo cells carrying APC R1114X with G418 (50, 100
and 200 mg/ml) or negamycin (1 mg/ml). As a control, LoVo cells were cotransfected with the pTOPGlow reporter plasmid and either the APC-
targeting siRNA (siRNA APC) or a non-targeting siRNA (siRNA NT) and treated with G418 (200 mg/ml). (E) Effect of the siRNA targeting APC
mRNA. We transiently transfected LoVo cells with an siRNA targeting (siRNA APC) or not targeting (siRNA NT) APC mRNA. Quantitative PCR
was used to determine mRNA levels. Results are expressed relative to the amount of mRNA in the presence of siRNA NT. Mean values are
presented, together with the SEM (n=3).
doi:10.1371/journal.pone.0024125.g002
Readthrough of PTCs in the APC Gene
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e24125Conclusion
In this study, we investigated the ability of readthrough-
inducing molecules to induce the production of a functional APC
protein in cells carrying various nonsense mutations in the APC
gene. Biological activity was detected for the two nonsense
mutations most responsive to aminoglycoside treatment
(R1114X and L360X) and this activity was directly proportional
to the readthrough levels measured with a dual reporter system.
This study shows that readthrough inducers, such as aminoglyco-
side and negamycin, can reactivate the APC tumor suppressor
gene in cancer cells. It provides a rational strategy for identifying
patients likely to respond and therefore more likely to benefit from
treatment with readthrough inducers. A recent study has provided
the proof-of-principle that the re-expression of a full-length APC
protein after treatment with readthrough inducers reduces tumor
size in a xenograft mouse [12]. Moreover, we have recently shown
that the treatment of cells carrying a nonsense mutation in the p53
tumor suppressor gene leads to the re-expression of a full-length
protein able to trigger apoptosis in tumor cells in culture [11]. All
these data suggest that molecules inducing stop-codon read-
through could potentially be used not only to treat genetic diseases,
but also to diversify the existing arsenal of treatments for cancer
and as a rational basis for the development of new personalized
treatment strategies.
Materials and Methods
Cell lines and cell culture
All cells were cultured in DMEM plus GlutaMAX (Invitrogen),
supplemented with 10% fetal calf serum (FCS, Invitrogen) and
100 U/ml penicillin/streptomycin. Cells were incubated in a
humidified atmosphere containing 5.5% CO2,a t3 7 uC. NIH3T3
(kindly provided by Marc Sitbon) cells are embryonic mouse
fibroblasts. LoVo (APC R1114X and del 1 bp 1430, kindly
provided by Franc ¸oise Praz, [30]) and DLD-1 (APC del 1 bp
1406, kindly provided by Franc ¸oise Praz, [31]) cells are epithelial
cells derived from a human colorectal adenocarcinoma. HeLa
(APC WT) cells are epithelial cells derived from a human cervix
adenocarcinoma (kindly provided by Fabrice Lejeune).
Readthrough quantification in cell culture
Complementary oligonucleotides corresponding to nonsense
mutations embedded in their natural context (sequences in Table 1)
were annealed and ligated into the pAC99 dual reporter plasmid,
as previously described [32]. This dual reporter allows the
quantification of stop-codon readthrough, through the measure-
ment of luciferase and beta-galactosidase (internal calibration)
activities, as previously described [16]. The readthrough levels of
nonsense mutations were analyzed in the presence or absence of
gentamicin. NIH3T3 cells were electroporated with 20 mgo f
reporter plasmid and, the following day, cells were rinsed and fresh
medium, with or without gentamicin, amikacin, negamycin or
G418 supplementation, was added. In these experiments, no cell
toxicity was observed for the doses of antibiotics used. Twenty-four
hours later, cells were harvested and lysed with trypsin-EDTA
(Invitrogen). Beta-galactosidase and luciferase activities were
assayed as previously described [32]. Readthrough efficiency was
estimated by calculating the ratio of luciferase to beta-galactosi-
dase activity obtained with the test construct and normalizing it
with respect to the ratio obtained with an in-frame control
construct. For each construct, at least five independent transfec-
tion experiments were performed. For readthrough quantification
in DLD-1, the same protocol was used, except that the calcium
phosphate method was used for transfection. For each construct,
at least three independent transfection experiments were per-
formed.
Expression plasmid constructs
pCMV APC WT was kindly provided by Dr. Bert Vogelstein
(Johns Hopkins Oncology Center, Baltimore). Directed mutagen-
esis was performed on a fragment of the APC gene to create the
APC L360X nonsense mutation (pCMV APC L360X). The
sequence of the re-inserted fragment was verified.
Western-blot analysis
LoVo cells were treated with G418 (200 mg/ml) for 72 h. The
medium was replaced and fresh antibiotics were added each day.
Cells were treated as previously described [11]. Total protein
levels were determined with the Bradford reagent (Biorad) and
extracts were denatured by incubation in Laemmli buffer for
5 min at 90uC. We subjected 100 mg of total protein to SDS-
PAGE in NuPAGE Novex 3/8% Tris/Acetate pre-cast gels
(Invitrogen). Proteins were transferred onto nitrocellulose mem-
branes overnight, as recommended by the manufacturer. Mem-
branes were saturated by incubation for 1 h in TBS supplemented
with 5% non fat milk powder, and incubated with the primary
monoclonal antibody, FE-9 (N-terminal epitope mapping between
amino acid residues 1 and 35 of APC; Calbiochem, 1/100).
Membranes were washed three times in TBS supplemented with
1% non fat milk powder and incubated with the secondary
antibody (horseradish peroxidase-conjugated anti-mouse IgG (1/
2500) or alkaline phosphatase-conjugated anti-mouse IgG (1/
7000) Promega) for 45 minutes. They were washed six times and
chemiluminescence was detected with ECL western blotting
detection reagents (Amersham, GE Healthcare).
Protein activity assays
The biological activity of APC was estimated with the
pTOPGlow vector (kindly provided by Dr. Marc Van de
Wetering, University Hospital Utrecht, the Netherlands).
DLD-1 cells were cotransfected with pCMV L360X (4 mg),
pTOPGlow or pFOPGlow (10 mg) and pCMVLacZ (2 mg), by the
calcium phosphate method. Each DNA precipitate was split
between two wells of a six-well plate. Antibiotics (10 mg/ml to
200 mg/ml G418; 800 mg/ml gentamicin; 2 mg/ml amikacin;
1 mg/ml negamycin) were added immediately after transfection,
except for G418, which was added the day after. The medium was
replaced daily and fresh antibiotics were added. We prepared
Figure 3. Western blot. LoVo cells were left untreated or were
treated with G418 (200 mg/ml) for 72 hours. Western blots were probed
with the FE-9 antibody directed against the N-terminus of APC. The
truncated forms corresponding to the mutated alleles present in LoVo
cells are indicated by arrows. An extract from HeLa cells (APC WT) was
used as a control; a band was detected at 311 kDa.
doi:10.1371/journal.pone.0024125.g003
Readthrough of PTCs in the APC Gene
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enzymatic activities.
For LoVo cells, antibiotics (G418 at concentrations of 50, 100
and 200 mg/ml; 1 mg/ml negamycin) were added the day before
transfection and on each subsequent day. LoVo cells were
cotransfected, by the calcium phosphate method, with TOPGlow
or FOPGlow (10 mg) and pCMVLacZ (2.8 mg) to normalize for
transfection efficiency, cell viability and protein extraction
variability. Each DNA precipitate was split between two wells of
a six-well plate. Three days after transfection, protein extracts
were prepared and enzymatic activities were measured.
For each cell line, at least three independent transfection
experiments were performed.
siRNA transfections
In LoVo cells, protein activity was determined as described
above. Cells were transfected with siRNA targeting mRNA APC
(Dharmacon ON-TARGET plus J-003869-12) or NS, nontarget-
ing (Dharmacon ON-TARGET plus control siRNA#1), in the
presence of DharmaFECT Duo (Thermo Scientific; 1.3 mgo f
siRNA per well of a six-well plate), 24 h after their initial
transfection as described above. Transfected cells were immedi-
ately incubated in medium with or without G418 (200 mg/ml)
supplementation. Three days after transfection, the cells were
harvested and luciferase and beta-galactosidase activities were
assayed as described above. At least four independent transfection
experiments were performed.
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